Konruns(SH:603590) Orient Securities·2025-05-26 07:31Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 38.64 CNY based on a 46x PE for 2025 [2][5]. Core Insights - The company experienced a significant decline in revenue and profit in 2024, with a revenue of 825 million CNY (down 10.3% YoY) and a net profit of 42 million CNY (down 71.9% YoY). However, the first quarter of 2025 shows signs of recovery, with a revenue of 212 million CNY (up 6.4% YoY) and a net profit of 44 million CNY (up 6.8% YoY) [10]. - The company is undergoing a transformation in its marketing strategy, shifting from an alliance model to a digital self-operated model, which has led to improved operational efficiency and reduced sales expenses [10]. - The clinical pipeline is progressing well, with several key products in various stages of development, indicating strong long-term growth potential [10]. Financial Performance Summary - Revenue Forecast: The company is projected to generate revenues of 969 million CNY in 2025, 1,141 million CNY in 2026, and 1,289 million CNY in 2027, reflecting a growth rate of 17.4%, 17.8%, and 12.9% respectively [4]. - Profitability Metrics: The operating profit is expected to rebound significantly to 217 million CNY in 2025, with a growth rate of 454.7% YoY, and further increase to 285 million CNY in 2026 and 337 million CNY in 2027 [4]. - Earnings Per Share (EPS): The EPS is forecasted to be 0.84 CNY in 2025, 1.14 CNY in 2026, and 1.40 CNY in 2027 [4]. - Margins: The gross margin is expected to remain stable around 89.7% to 89.8% over the forecast period, while the net margin is projected to improve from 13.8% in 2025 to 17.3% in 2027 [4].